ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
Background - With an increased uptake of genomic profiling in clinical practice and the evolving complexity of diagnostic modalities, vast amounts of complex data need to be properly interpreted and integrated into an individualised care plan. To address these challenges, molecular tumour boards (MT...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 2025
|
| In: |
Annals of oncology
Year: 2025, Volume: 36, Issue: 6, Pages: 614-625 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2025.02.009 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.annonc.2025.02.009 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753425000808 
|
| Author Notes: | C.B. Westphalen, L. Boscolo Bielo, P. Aftimos, H. Beltran, M. Benary, D. Chakravarty, M. Collienne, R. Dienstmann, A. El Helali, J. Gainor, P. Horak, C. Le Tourneau, C. Marchiò, C. Massard, F. Meric-Bernstam, C. Pauli, G. Pruneri, F. Roitberg, H.E.G. Russnes, D.B. Solit, N. Starling, V. Subbiah, D. Tamborero, N. Tarazona, C. Turnbull, J. van de Haar, F. André, J. Mateo & G. Curigliano |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 193678968X | ||
| 003 | DE-627 | ||
| 005 | 20250925100630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250925s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2025.02.009 |2 doi | |
| 035 | |a (DE-627)193678968X | ||
| 035 | |a (DE-599)KXP193678968X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Westphalen, Christoph Benedikt |d 1980- |e VerfasserIn |0 (DE-588)138248273 |0 (DE-627)600665313 |0 (DE-576)306892243 |4 aut | |
| 245 | 1 | 0 | |a ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice |c C.B. Westphalen, L. Boscolo Bielo, P. Aftimos, H. Beltran, M. Benary, D. Chakravarty, M. Collienne, R. Dienstmann, A. El Helali, J. Gainor, P. Horak, C. Le Tourneau, C. Marchiò, C. Massard, F. Meric-Bernstam, C. Pauli, G. Pruneri, F. Roitberg, H.E.G. Russnes, D.B. Solit, N. Starling, V. Subbiah, D. Tamborero, N. Tarazona, C. Turnbull, J. van de Haar, F. André, J. Mateo & G. Curigliano |
| 264 | 1 | |c June 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 6. April 2025, Artikelversion: 20. Mai 2025 | ||
| 500 | |a Gesehen am 25.09.2025 | ||
| 520 | |a Background - With an increased uptake of genomic profiling in clinical practice and the evolving complexity of diagnostic modalities, vast amounts of complex data need to be properly interpreted and integrated into an individualised care plan. To address these challenges, molecular tumour boards (MTBs) have been widely established. As of today, no international recommendations regulating the composition and workflows of MTBs have been defined. - Methods - ESMO’s Precision Oncology Working Group (POWG) established an international expert panel in precision oncology and defined core areas of interest. After several consultations and through an expert consensus process, the group reached a consensus level for each recommendation. - Results - The group defined five components in the MTB process that are critical to its function and clinical use: (i) the primary task of MTBs consists in providing genomic-informed clinical recommendations, particularly for cases exhibiting complex genomic alterations; (ii) to achieve this, MTBs should encompass interdisciplinary expertise, with key roles for oncologists with genomic expertise, pathologists with molecular training and clinical geneticists; (iii) MTBs’ recommendations should be documented in a structured report that includes genomic-informed treatment strategies, management plans for potential tumour-detected germline alterations and guidance for additional genomic testing; (iv) structured follow-up processes should be implemented for monitoring the clinical effectiveness of MTBs recommendations and (v) finally, the panel proposed quality indicators for operating MTBs, including turnaround times for cases discussion and the proportion of cases for which actionable recommendations and clinical trial enrolments were successfully implemented. - Conclusions - These ESMO’s POWG recommendations can serve as a guidance and help to define quality standards for MTBs to allow for harmonisation and to further expedite the integration of precision oncology into clinical practice. | ||
| 650 | 4 | |a ESMO | |
| 650 | 4 | |a molecular tumour boards | |
| 650 | 4 | |a MTB | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a precision oncology | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Boscolo Bielo, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aftimos, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beltran, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Benary, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chakravarty, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Collienne, Maike |e VerfasserIn |0 (DE-588)1081846593 |0 (DE-627)846741741 |0 (DE-576)45484364X |4 aut | |
| 700 | 1 | |a Dienstmann, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a El Helali, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gainor, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Horak, Peter |e VerfasserIn |0 (DE-588)1156426111 |0 (DE-627)1019252839 |0 (DE-576)502179961 |4 aut | |
| 700 | 1 | |a Le Tourneau, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marchiò, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Massard, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meric-Bernstam, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pauli, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pruneri, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roitberg, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Russnes, H. E. G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Solit, D. B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Starling, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Subbiah, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tamborero, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tarazona, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Turnbull, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a van de Haar, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a André, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mateo, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Curigliano, G. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 36(2025), 6 vom: Juni, Seite 614-625 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice |
| 773 | 1 | 8 | |g volume:36 |g year:2025 |g number:6 |g month:06 |g pages:614-625 |g extent:12 |a ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2025.02.009 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753425000808 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250925 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1156426111 |a Horak, Peter |m 1156426111:Horak, Peter |d 910000 |e 910000PH1156426111 |k 0/910000/ |p 11 | ||
| 998 | |g 1081846593 |a Collienne, Maike |m 1081846593:Collienne, Maike |d 60000 |e 60000PC1081846593 |k 0/60000/ |p 7 | ||
| 999 | |a KXP-PPN193678968X |e 4775939785 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"title":[{"title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","title_sort":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice"}],"person":[{"display":"Westphalen, Christoph Benedikt","family":"Westphalen","role":"aut","given":"Christoph Benedikt"},{"display":"Boscolo Bielo, L.","role":"aut","given":"L.","family":"Boscolo Bielo"},{"family":"Aftimos","given":"P.","role":"aut","display":"Aftimos, P."},{"display":"Beltran, H.","given":"H.","role":"aut","family":"Beltran"},{"display":"Benary, M.","given":"M.","role":"aut","family":"Benary"},{"role":"aut","given":"D.","family":"Chakravarty","display":"Chakravarty, D."},{"role":"aut","given":"Maike","family":"Collienne","display":"Collienne, Maike"},{"display":"Dienstmann, R.","given":"R.","role":"aut","family":"Dienstmann"},{"display":"El Helali, A.","family":"El Helali","given":"A.","role":"aut"},{"family":"Gainor","role":"aut","given":"J.","display":"Gainor, J."},{"display":"Horak, Peter","family":"Horak","given":"Peter","role":"aut"},{"family":"Le Tourneau","role":"aut","given":"C.","display":"Le Tourneau, C."},{"given":"C.","role":"aut","family":"Marchiò","display":"Marchiò, C."},{"family":"Massard","role":"aut","given":"C.","display":"Massard, C."},{"display":"Meric-Bernstam, F.","family":"Meric-Bernstam","role":"aut","given":"F."},{"display":"Pauli, C.","given":"C.","role":"aut","family":"Pauli"},{"display":"Pruneri, G.","given":"G.","role":"aut","family":"Pruneri"},{"role":"aut","given":"F.","family":"Roitberg","display":"Roitberg, F."},{"display":"Russnes, H. E. G.","given":"H. E. G.","role":"aut","family":"Russnes"},{"given":"D. B.","role":"aut","family":"Solit","display":"Solit, D. B."},{"family":"Starling","role":"aut","given":"N.","display":"Starling, N."},{"display":"Subbiah, V.","given":"V.","role":"aut","family":"Subbiah"},{"role":"aut","given":"D.","family":"Tamborero","display":"Tamborero, D."},{"display":"Tarazona, N.","role":"aut","given":"N.","family":"Tarazona"},{"display":"Turnbull, C.","family":"Turnbull","given":"C.","role":"aut"},{"display":"van de Haar, J.","family":"van de Haar","given":"J.","role":"aut"},{"family":"André","given":"F.","role":"aut","display":"André, F."},{"display":"Mateo, J.","given":"J.","role":"aut","family":"Mateo"},{"family":"Curigliano","given":"G.","role":"aut","display":"Curigliano, G."}],"recId":"193678968X","name":{"displayForm":["C.B. Westphalen, L. Boscolo Bielo, P. Aftimos, H. Beltran, M. Benary, D. Chakravarty, M. Collienne, R. Dienstmann, A. El Helali, J. Gainor, P. Horak, C. Le Tourneau, C. Marchiò, C. Massard, F. Meric-Bernstam, C. Pauli, G. Pruneri, F. Roitberg, H.E.G. Russnes, D.B. Solit, N. Starling, V. Subbiah, D. Tamborero, N. Tarazona, C. Turnbull, J. van de Haar, F. André, J. Mateo & G. Curigliano"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"June 2025"}],"id":{"eki":["193678968X"],"doi":["10.1016/j.annonc.2025.02.009"]},"note":["Online verfügbar: 6. April 2025, Artikelversion: 20. Mai 2025","Gesehen am 25.09.2025"],"relHost":[{"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"pubHistory":["1.1990 -"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"origin":[{"dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"part":{"year":"2025","issue":"6","pages":"614-625","volume":"36","text":"36(2025), 6 vom: Juni, Seite 614-625","extent":"12"},"recId":"320428796","disp":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceAnnals of oncology"}]} | ||
| SRT | |a WESTPHALENESMOPRECIS2025 | ||